FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Kavanugh Rulings For and Against FDA
07/11/2018
 
 
TXT FDA Wants to Build Medical Data Enterprise
07/10/2018
 
 
TXT Regulating Mobile Medical Apps
07/09/2018
 
 
TXT New, Updated FDA Gene Therapy Guidances
07/11/2018
 
 
TXT Concerns About Expanded 510(k)
07/13/2018
 
 
TXT FDA Releases 32-page Hospira India FDA-483
07/13/2018
 
 
TXT Materials Promote Unapproved Arog Drug: OPDP
07/11/2018
 
 
TXT FDA Has ‘Strayed from Its Mission’: White Paper
07/10/2018
 
 
TXT Indications, Usage Content Guidance
07/09/2018
 
 
TXT Gottlieb Weighs In on Advanced Manufacturing
07/13/2018
 
 
TXT Drug Shortage Group Wants New Solutions
07/13/2018
 
 
TXT Consumers Getting ‘Fake’ Warning Letters: FDA
07/13/2018
 
 
TXT DoJ Launches Fraud Task Force
07/11/2018
 
 
TXT Canadian Companies Sentenced in Unapproved Drugs Scheme
07/16/2018
 
 
TXT Firms Recall Valsartan-containing Products Due to Impurity
07/16/2018
 
 
TXT FDA Extends Review of Invokana Supplemental NDA
07/16/2018
 
 
TXT Product Approval Summaries
07/15/2018
 
 
TXT Latest Federal Register Notices
07/15/2018
 
 
TXT Since Our Last Issue ...
07/15/2018
 
 
TXT Hypertension Drugs Draft Guidance
07/13/2018
 
 
TXT CDK4/6 Inhibitors Help in Breast Cancer: FDA Study
07/11/2018
 
 
TXT Company Comments on Therapeutic Protein Interactions
07/11/2018
 
 
TXT API Deviations in Zhuhai Inspection
07/10/2018
 
 
TXT Smallpox Drug Development Guidance
07/10/2018
 
 
TXT Stokes Healthcare FDA-483
07/10/2018
 
 
TXT Latest FDA Warning Letters
07/10/2018
 
 
TXT Fluoroquinolone Antibiotic Label Changes Ordered
07/10/2018
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving